Newsletter Signup x
One of the major specific challenges in childhood cancer is Group 3 medulloblastoma driven by the over-abundance of a gene called MYC (MYC-MBGroup3). This tumour group occurs almost exclusively in young children and is essentially incurable, contributing significantly to overall childhood cancer death rates. New targeted treatments are urgently needed to improve the outlook for children with high-risk medulloblastoma. The INSTINCT-MB project will seek to develop new treatments for MYC-MBGroup3, using new drugs and promising new immunotherapies known as Chimeric Antigen Receptor T-cells (CAR-T) therapies.
INSTINCT-MB: Strategic implementation of novel combination therapeutics for high-risk medulloblastoma
Professor Steve Clifford
Newcastle University Centre for Cancer, Newcastle University
Newcastle upon Tyne, NE1 7RU
1 February 2022
60 months
£712,027 co-funded by Blue Skye Thinking and Little Hero
Patient Story – Ellie the vlogger
Hi everyone. My name is Ellie. When I was 14 I was diagnosed with Alveolar Rhabdomyosarcoma. This is my
Read moreInvestigating inherited genes that are linked to the development of rhabdomyosarcoma
Rhabdomyosarcoma (RMS) is a rare childhood cancer. Dr Tischkowitz wants to find out which genes make children more likely
Read moreFinding new ways to beat childhood neuroblastoma
Neuroblastoma is one of the most common childhood tumours. We’ve been working hard to develop more effective treatments, and
Read more